List of Invokamet Xr drug patents
Invokamet Xr is owned by Janssen Pharms.
Invokamet Xr contains Canagliflozin; Metformin Hydrochloride.
Invokamet Xr has a total of 5 drug patents out of which 0 drug patents have expired.
Invokamet Xr was authorised for market use on 20 September, 2016.
Invokamet Xr is available in tablet, extended release;oral dosage forms.
Invokamet Xr can be used as reduction of risk of major adverse cardiovascular events in the treatment of type 2 diabetes mellitus patients; treatment of type 2 diabetes mellitus; reduction of risk of end stage kidney disease, doubling of serum creatinine, cardiovascular death, and hospitalization for heart failure in the treatment of type 2 diabetes mellitus patients, treatment of type 2 diabetes mellitus; reduction of risk of major adverse cardiovascular events in the treatment of type 2 diabetes mellitus patients; reduction of risk of end stage kidney disease, doubling of serum creatinine, cardiovascular death, and hospitalization for heart failure in the treatment of type 2 diabetes mellitus patients.
The generics of Invokamet Xr are possible to be released after 26 February, 2029.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7943788 | JANSSEN PHARMS | Glucopyranoside compound |
Jul, 2027
(4 years from now) | |
| US8513202 | JANSSEN PHARMS | Crystalline form of 1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene hemihydrate |
Dec, 2027
(4 years from now) | |
| US7943582 | JANSSEN PHARMS | Crystalline form of 1-(β-D-glucopyransoyl)-4-methyl-3-[5-(4-fluorophenyl)-2- thienylmethyl]benzene hemihydrate |
Feb, 2029
(5 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8785403 | JANSSEN PHARMS | Glucopyranoside compound |
Jul, 2024
(1 year, 4 months from now) | |
| US8222219 | JANSSEN PHARMS | Glucopyranoside compound |
Apr, 2025
(2 years from now) | |
Drugs and Companies using CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient
Market Authorisation Date: 20 September, 2016
Treatment: Reduction of risk of major adverse cardiovascular events in the treatment of type 2 diabetes mellitus patients; Treatment of type 2 diabetes mellitus; Reduction of risk of end stage kidney disease, doubling of serum creatinine, cardiovascular death, and hospitalization for heart failure in the treatment of type 2 diabetes mellitus patients
Dosage: TABLET, EXTENDED RELEASE;ORAL
INVOKAMET XR family patents
45
United States
14
Japan
11
European Union
10
China
9
Argentina
9
Taiwan, Province of China
8
EA
8
South Africa
8
Canada
8
Australia
7
Ukraine
6
Spain
5
New Zealand
5
Norway
5
Korea, Republic of
5
Ecuador
4
Malaysia
4
Brazil
4
Costa Rica
4
Mexico
4
Yugoslavia
4
Iceland
4
Israel
3
Portugal
3
Croatia
3
Peru
3
Cyprus
3
Slovenia
3
Poland
3
Denmark
2
Singapore
2
Hungary
2
ME
2
RS
1
El Salvador
1
Uruguay
1
Panama
1
Guatemala
1
Colombia
1
Hong Kong
1
Honduras
1
Nicaragua
1
Lithuania
1
Luxembourg
1
Chile
1
Netherlands
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic